Updates are available Correction dated 2021-11-03
Click to view Correction: https://doi.org/10.1038/s41586-021-04149-z
-
Authors
Jin, Xin https://orcid.org/0000-0003-4167-1743
Demere, Zelalem
Nair, Karthik
Ali, Ahmed
Ferraro, Gino B. https://orcid.org/0000-0002-1587-4259
Natoli, Ted
Deik, Amy
Petronio, Lia
Tang, Andrew A.
Zhu, Cong
Wang, Li
Rosenberg, Danny
Mangena, Vamsi https://orcid.org/0000-0003-2662-0366
Roth, Jennifer
Chung, Kwanghun https://orcid.org/0000-0002-8167-3340
Jain, Rakesh K. https://orcid.org/0000-0001-7571-3548
Clish, Clary B. https://orcid.org/0000-0001-8259-9245
Vander Heiden, Matthew G. https://orcid.org/0000-0002-6702-4192
Golub, Todd R. https://orcid.org/0000-0003-0113-2403
- License Information
-
More Information
Article History
Received: 17 December 2018
Accepted: 26 August 2020
First Online: 9 December 2020
Change Date: 3 November 2021
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41586-021-04149-z
Competing interests
: T.R.G. receives research funding unrelated to this project from Bayer HealthCare, Novo Ventures and Calico Life Sciences; holds equity in FORMA Therapeutics; is a consultant to GlaxoSmithKline; and is a founder of Sherlock Biosciences. M.G.V.H. is a scientific advisory board member for Agios Pharmaceuticals, Aeglea Biotherapeutics, Auron Therapeutics and iTeos Therapeutics. R.K.J. received a honorarium from Amgen; consultant fees from Chugai, Merck, Ophthotech, Pfizer, SPARC and SynDevRx; owns equity in Accurius, Enlight, Ophthotech and SynDevRx; and serves on the Boards of Trustees of Tekla Healthcare Investors, Tekla Life Sciences Investors, Tekla Healthcare Opportunities Fund and Tekla World Healthcare Fund. No reagents or funding from these organizations were used in this study. X.J. and T.R.G. are named as inventors on pending PCT Patent Application No. PCT/US20/29584 filed by The Broad Institute, which describes compositions and methods for characterizing the metastatic potential of cancer cell lines. The other authors declare no competing interests.
